STC-1 alleviates airway inflammation by regulating epithelial cell apoptosis through the 5-LO pathway

Area of Science:

• Immunology
• Cell Biology
• Pharmacology

Background:

• Airway inflammation is central to asthma pathogenesis.
• Stanniocalcin-1 (STC-1) possesses known antioxidant, anti-inflammatory, and anti-apoptotic properties.
• The role of STC-1 in asthma-related airway inflammation requires investigation.

Purpose of the Study:

• To investigate the therapeutic effects of STC-1 on airway inflammation in asthma.
• To elucidate the underlying mechanisms of STC-1's action, focusing on signaling pathways and key mediators.

Main Methods:

• Utilized a murine model of ovalbumin (OVA)-induced asthma.
• Employed lipopolysaccharide (LPS)-challenged BEAS-2B cells for in vitro studies.
• Assessed inflammatory cell infiltration, mucus secretion, cytokine levels, apoptosis, p38 MAPK signaling, and 5-lipoxygenase (5-LO) expression.

Main Results:

• STC-1 treatment reduced inflammatory cell infiltration, mucus production, pro-inflammatory cytokines, and apoptosis in asthmatic mice.
• STC-1 inhibited p38 MAPK signaling, 5-LO expression, and leukotriene B4 (LTB4) production in vitro.
• Transforming growth factor-beta (TGF-β) reversed STC-1's protective effects by upregulating 5-LO.

Conclusions:

• STC-1 demonstrates significant protective effects against airway inflammation and apoptosis in asthma models.
• STC-1 exerts its anti-inflammatory effects partly by inhibiting the p38 MAPK pathway and reducing 5-LO expression.
• STC-1 holds promise as an adjunctive therapeutic agent for managing asthma, particularly through its modulation of 5-LO.